TRIB Trinity Biotech PLC ADS

Trinity Biotech plc to Announce Second Quarter Fiscal Year 2019 Financial Results

Trinity Biotech plc to Announce Second Quarter Fiscal Year 2019 Financial Results

Conference Call Scheduled for August 20, 2019 at 11:00 am EASTERN

DUBLIN, Ireland, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the second quarter fiscal year 2019 on Tuesday, August 20, 2019. The Company has scheduled a conference call for that same day, Tuesday, August 20, 2019 at 11:00am ET (4:00pm BST) to discuss the results of the quarter. 

Interested parties can access the call by dialing:
USA:1-844-861-5499
International:1-412-317-6581
Conference ID #:10134422

A simultaneous webcast of the call can be accessed at:

A replay of the call can be accessed until August 27, 2019 by dialing:
USA: 1-877-344-7529
International: 1-412-317-0088
Conference ID #:10134422

The webcast of the call will be available for 30 days at: 

Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.

Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: .

Contact

Kevin Tansley

Trinity Biotech plc

(353)-1-2769800

E-mail:

Joe Diaz

Lytham Partners, LLC

Investor Relations

602-889-9700

EN
15/08/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Trinity Biotech PLC ADS

 PRESS RELEASE

Trinity Biotech Secures $25 Million Financing Commitment to Support Gr...

Trinity Biotech Secures $25 Million Financing Commitment to Support Growth Initiatives - Agreement provides additional funding tool of up to $25 million over a period of up to 36 months - Underpins the Company’s ambitions to expand its commercialisation activities and advance its innovation agenda DUBLIN, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has entered into a $25 million Standby Equity Purchase A...

 PRESS RELEASE

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global...

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares DUBLIN, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice on February 19, 2026 from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company no longer meets the requirement in Nasdaq Listing Rule 5450(b) that listed securities maintain a minimum market value of publicly held shares (...

 PRESS RELEASE

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global...

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Nasdaq Minimum Bid Price Requirement DUBLIN, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice on February 11, 2026 from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), requiring that listed securities maintain a minimum bid price of $1.00 per share, based on the...

 PRESS RELEASE

Trinity Biotech Secures Regulatory Approval for Commencement of Upstre...

Trinity Biotech Secures Regulatory Approval for Commencement of Upstream Manufacturing Activities of Uni-Gold™ HIV Rapid Test Under Its Offshored and Outsourced Model, Supporting Financial Performance Transformation Approval Marks Final Regulatory Milestone Required to Enable Launch of Upstream Manufacturing Activities Under New Offshored & Outsourced Production Model Expected to Drive Gross Margin Expansion, Improve Working Capital Efficiency, and Enhance Long‑Term Scalability  Represents a Key Final Component of the Company’s Comprehensive Transformation Plan DUBLIN, Ireland, Feb. 10, 2...

 PRESS RELEASE

Trinity Biotech Glucose Monitoring Innovation Achieves Unique Global R...

Trinity Biotech Glucose Monitoring Innovation Achieves Unique Global Recognition: Diabetes Care Premier Hb9210™ HbA1c Analyser Becomes the Only System Awarded Prestigious IFCC Gold Classification for 2026 – Reinforces Trinity Biotech’s growing position as a key player in diabetes care innovation – Senior commercial executives of Trinity Biotech are attending the World Health Expo from February 10-12, 2026 DUBLIN, Ireland, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management sol...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch